Moderna

mRNA Vaccines and Therapeuticsmodernatx.com

Moderna is a publicly traded Cambridge, MA-based biotechnology company (NASDAQ: MRNA) that develops mRNA-based vaccines and therapeutics, with four approved products (Spikevax, mNEXSPIKE, mRESVIA, mCOMBRIAX) and a 45-program pipeline serving government health agencies, healthcare providers, and patients across infectious disease, oncology, and rare diseases globally.

Company typePublic
Founded2010
HeadquartersCambridge, United States
Headcount5,001–10,000
GTM typeB2B
OfferingHardware or Manufacturing

What Moderna does

Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company founded in 2010 that develops mRNA-based medicines and vaccines using its proprietary messenger RNA platform and lipid nanoparticle (LNP) delivery technology. The company has four commercially approved products: Spikevax and mNEXSPIKE (COVID-19 vaccines), mRESVIA (RSV vaccine for adults 60+), and mCOMBRIAX (combined flu/COVID vaccine approved by the European Commission), supported by a pipeline of 45 development programs across 36 ongoing clinical trials spanning respiratory vaccines, oncology (including personalized neoantigen therapies partnered with Merck), and rare disease therapeutics. The company operates 4,700 employees globally with offices, regional headquarters, and manufacturing in more than 18 countries.

Moderna generates revenue primarily through transactional vaccine product sales to government health agencies and healthcare providers, supplemented by government contracts and grants (e.g., $176M from HHS for bird flu, $54.3M from CEPI for pandemic flu), and strategic partnership milestone payments (notably the Merck oncology collaboration). Its go-to-market is sales-led, focused on regulatory approvals and contracting with national governments and public health systems, with distribution through government procurement, healthcare provider networks, and regional affiliate offices across North America, Europe, Asia-Pacific, and Latin America.

The company is leveraging AI through its proprietary mRNA Design Studio (part of the Scientific Intelligence Engine) for automated sequence design and preclinical data analysis, and through a company-wide OpenAI ChatGPT Enterprise deployment that has produced over 750 custom GPT assistants across functions. Moderna's stated strategic objective is to launch up to 15 products by 2027, transitioning from a single-product COVID vaccine company into a diversified multi-modality mRNA therapeutics platform.

Moderna firmographics

Firmographics

Name: Moderna
Legal name: Moderna, Inc.
Website: https://modernatx.com
Company type: Public
Founded year: 2010
Operating status: Operating
Headcount range: 5,001–10,000 employees
Short description: Moderna is a publicly traded Cambridge, MA-based biotechnology company (NASDAQ: MRNA) that develops mRNA-based vaccines and therapeutics, with four approved products (Spikevax, mNEXSPIKE, mRESVIA, mCOMBRIAX) and a 45-program pipeline serving government health agencies, healthcare providers, and patients across infectious disease, oncology, and rare diseases globally.
Ownership category
akta.pro rank

Moderna industry classification

Industry

Product category: mRNA Vaccines and Therapeutics
NAICS: Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC: Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry: Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
akta.pro secondary industries: Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

MRNA medicines
Vaccine development
Biotechnology therapeutics
Oncology vaccines
Rare disease treatments

Where Moderna is headquartered

Location

Headquarters

HQ city: Cambridge
HQ country: United States
HQ region: North America

Offices10 records

Markets served

Moderna business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

Vaccine Product Sales: Moderna generates revenue from sales of approved mRNA vaccines including Spikevax (COVID-19), mRESVIA (RSV), and mNEXSPIKE. Revenue is transaction-based from government and commercial customers.
Government Contracts & Grants: Funding from governments for vaccine development and pandemic preparedness, including $176 million from US government for bird flu vaccine and CEPI funding for Ebola vaccine.
Strategic Partnerships: Collaboration revenue from partnerships such as Merck (cancer vaccines), with potential milestone payments and royalties.

Pricing tiers

Model	Billing	Price
Transaction based/ take rate	Pay-as-you-go	Government vaccine contracts

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Moderna product offering

Product offering

Core offering

Moderna develops and commercializes mRNA-based medicines, with a current commercial portfolio of four approved vaccines—Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and mCOMBRIAX (a flu + COVID combination vaccine)—and a pipeline of more than 45 development programs covering respiratory, oncology, latent, and rare disease indications. The company sells directly to governments and through healthcare provider channels and earns partnership revenues from collaborators such as Merck.

Product overview

Moderna is a diversified multi-modality biotechnology company pioneering mRNA medicines. The company's portfolio consists of four commercially approved products: SPIKEVAX® (COVID-19 vaccine), mNEXSPIKE® (updated COVID-19 vaccine), mRESVIA® (RSV vaccine), and mCOMBRIAX (flu plus COVID combination vaccine). These commercial vaccines are supported by an extensive pipeline of 45+ development programs spanning respiratory vaccines, latent and other vaccines (norovirus, CMV, EBV, HIV, Lyme disease, Nipah, mpox), oncology therapeutics including personalized cancer vaccines (intismeran autogene/mRNA-4157), T-cell engagers, and rare disease therapeutics for conditions like propionic acidemia, methylmalonic acidemia, and cystic fibrosis. The company leverages its mRNA platform combined with AI and machine learning tools including the mRNA Design Studio to accelerate discovery and development across its diverse therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

SPIKEVAX: Brand name for Moderna's COVID-19 vaccine (mRNA-1273)
mNEXSPIKE
mRESVIA
mFLUSIVA
mCOMBRIAX
mRNA Design Studio
Intismeran
mRNA Design Studio

Products and services

SPIKEVAX (mRNA-1273 COVID-19 Vaccine) mRNA-based COVID-19 vaccine originally authorized for emergency use and now commercially distributed globally for COVID-19 immunization.
mNEXSPIKE (COVID-19 Vaccine) Updated formulation of Moderna's COVID-19 vaccine with improved stability and efficacy profiles.
mRESVIA (mRNA-1345 RSV Vaccine) mRNA-based respiratory syncytial virus (RSV) vaccine approved for adults 60 and older, with FDA advisory committee recommending expansion to adults 50 and older.
mCOMBRIAX (Flu + COVID Combination Vaccine) Combined mRNA-based flu and COVID-19 vaccine approved by the European Commission for adults 50 and older.
mRNA-1018 (Pandemic Flu Vaccine) mRNA-based pandemic influenza vaccine targeting H5N8 bird flu and H7N9 strains, funded by CEPI for Phase 3 testing.
Intismeran Autogene (mRNA-4157/V940) Individualized neoantigen therapy developed in partnership with Merck for adjuvant melanoma and other cancers; five-year Phase 2b data showed reduced recurrence risk when combined with Keytruda.
mRNA-4194 (Lynch Syndrome Cancer Vaccine) Investigational mRNA-based cancer vaccine for Lynch syndrome patients, encoding 194 frameshift antigen targets to prevent cancer development; developed with the University of Oxford.
Bundibugyo Ebola Vaccine (mRNA) mRNA-based vaccine candidate for the Bundibugyo Ebola strain, receiving CEPI funding for development under an emergency authorization pathway.

Quantifiable outcome

27% higher efficacy against flu compared to standard vaccines in Phase 3 trials for adults 50+
+4 more outcomes

Companies that use Moderna

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Moderna technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Moderna partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

University of OxfordcoreStrategic or Co-development Partner · 8 June 2026Partnership for Lynch syndrome cancer vaccine trial (mRNA-4194) authorized by UK MHRA. Part of 10-year strategic partnership with UK Government established in 2022 including over 20 clinical trials across 135 UK centers with more than 14,500 participants.
Merck (MSD outside US)coreStrategic or Co-development PartnerCollaboration on intismeran autogene (mRNA-4157/V940), an individualized neoantigen therapy for multiple cancers. Five-year Phase 2b data showed 49% reduction in melanoma recurrence/death when combined with Keytruda. Partnership expanding across adjuvant melanoma, NSCLC, renal cell carcinoma, and bladder cancer with Phase 3 trials ongoing.
Vertex PharmaceuticalsminorStrategic or Co-development PartnerCollaboration on mRNA-3692 for cystic fibrosis treatment in Phase 2 development. Partnership ongoing despite discontinued mRNA-based CF treatment collaboration noted in some reports.
OpenAIcoreTechnology or IntegrationModerna deployed ChatGPT Enterprise company-wide, with employees building over 750 custom GPT assistants within two months. 100% adoption achieved in legal department, averaging 120 conversations per user per week. Also collaborating on GPT-Rosalind specialized AI model for life sciences research.
ImmaticsminorStrategic or Co-development PartnerCollaboration on mRNA-4203 + anzu-cel (IMA203) for solid tumors cell therapy, in Phase 1 development.
IAVI (International AIDS Vaccine Initiative)minorStrategic or Co-development PartnerCollaboration on HIV vaccine development (mRNA-1645) in Phase 1, exploring mRNA technology for preventive HIV vaccines.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Moderna competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Moderna financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Moderna leadership team

Management profile

Number of profiles

Profiles11 records

Moderna subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Moderna funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Moderna M&A and investment

M&A and investment

M&A1 record

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moderna

What does Moderna do?

Is Moderna a public or private company?

Moderna is a public company. It is classified as public and is currently operating.

When was Moderna founded?

Moderna was founded in 2010. It employs 5,001 to 10,000 people.

Where is Moderna based?

Moderna is headquartered in Cambridge, United States, in the North America region.

How does Moderna make money?

Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are government Contracts & Grants and strategic Partnerships.

Does Moderna have an API?

No public API is recorded for Moderna.

What industry is Moderna in?

Moderna's product category is mRNA Vaccines and Therapeutics. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325414 and its SIC code is 2836.